Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18865627 | 0.73 | OPRL1 (0.38) | — | |
| SCHEMBL29691063 | 0.73 | OPRL1 (0.38) | — | |
| SCHEMBL20430172 | 0.72 | EPHX2 (0.32) | JAK2BTK | |
| SCHEMBL14833696 | 0.71 | PTGS1 (0.43) | CYP17A1 | |
| SCHEMBL14833491 | 0.71 | CYP17A1 (0.48) | CYP17A1HTR2AJAK2BTK | |
| SCHEMBL21177656 | 0.71 | LPL (0.39) | JAK2BTK | |
| SCHEMBL21624164 | 0.70 | SLC6A4 (0.42) | HTR1AJAK2BTK | |
| SCHEMBL29968120 | 0.70 | SLC6A4 (0.42) | HTR1AJAK2BTK | |
| SCHEMBL15995776 | 0.70 | JAK2 (0.36) | JAK2BTK | |
| SCHEMBL16006540 | 0.70 | CA12 (0.35) | JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| EP-2760870-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP1A2, CYP3A43, CYP4A22 | CYP17A1 35/4885HTR1A 2478/4885HTR2A 1501/4885 |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | CYP17A1 23/4885HTR1A 2801/4885HTR2A 1972/4885 |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | CYP17A1 23/4885HTR1A 2801/4885HTR2A 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.